Intersect ENT (NASDAQ:XENT) posted its quarterly earnings data on Tuesday. The medical equipment provider reported ($0.11) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.17) by $0.06, Bloomberg Earnings reports. Intersect ENT had a negative net margin of 19.81% and a negative return on equity of 15.96%. The company had revenue of $29.53 million for the quarter, compared to analyst estimates of $29.45 million.
Intersect ENT (NASDAQ XENT) traded down $0.40 during trading on Wednesday, reaching $35.85. 186,600 shares of the company were exchanged, compared to its average volume of 268,249. The stock has a market cap of $1,067.78, a price-to-earnings ratio of -56.90 and a beta of 0.79. Intersect ENT has a 12 month low of $13.15 and a 12 month high of $38.30.
A number of analysts recently weighed in on the stock. BidaskClub lowered shares of Intersect ENT from a “buy” rating to a “hold” rating in a research report on Tuesday. Zacks Investment Research raised shares of Intersect ENT from a “sell” rating to a “hold” rating in a research report on Friday, January 26th. JPMorgan Chase & Co. raised shares of Intersect ENT from a “neutral” rating to an “overweight” rating in a research report on Tuesday, January 2nd. Guggenheim reissued a “buy” rating and issued a $41.00 price objective on shares of Intersect ENT in a research report on Friday, December 15th. Finally, Canaccord Genuity reissued a “buy” rating and issued a $36.00 price objective on shares of Intersect ENT in a research report on Monday, December 11th. Five research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $33.38.
Intersect ENT Company Profile
Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.
Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.